Patents by Inventor Meiliana Tjandra
Meiliana Tjandra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240125772Abstract: The present disclosure provides compositions and methods for using fixed biological samples in partition-based assays. In at least one embodiment, the disclosure provides a composition comprising a fixed biological sample and an un-fixing agent contained in a partition, such as a discrete droplet. In some embodiments, the disclosure provides un-fixing agent compounds capable of catalytically cleaving crosslinks in fixed biological samples, particularly crosslinked nucleic acids, such as RNA.Type: ApplicationFiled: November 7, 2023Publication date: April 18, 2024Inventors: Joshua Delaney, Shalini Gohil, Jill Herschleb, Adam Lowe, Albert Kim, Meiliana Tjandra
-
Publication number: 20240117410Abstract: The present disclosure relates in some aspects to methods and compositions for in situ analysis involving catalytic de-crosslinking of biological samples.Type: ApplicationFiled: October 31, 2023Publication date: April 11, 2024Inventors: Joshua DELANEY, Shalini Gohil, Veronica Emelina Gonzalez Munoz, Joshua Gu, Albert Dale Kim, Yi Luo, Tathagata Mukherjee, Monica Nagendran, James Francis Perna, III, Kristen Nguyen Pham, Meiliana Tjandra
-
Publication number: 20240043914Abstract: The present disclosure generally relates to methods and compositions for in situ analysis or detection of analytes in a biological sample. More specifically, the present disclosure relates to methods for reducing autofluorescence in tissue samples, methods for analyzing tissue samples, and compounds for use in the same. The methods and compounds of the present disclosure may be especially suitable for analytical methods employing fluorescence in situ hybridization techniques over multiple cycles of imaging.Type: ApplicationFiled: August 7, 2023Publication date: February 8, 2024Inventors: Hong CHEN, Joshua Delaney, Yi Luo, Meiliana Tjandra
-
Publication number: 20240035071Abstract: The present disclosure relates in some aspects to methods and compositions for in situ analysis involving catalytic de-crosslinking of biological samples.Type: ApplicationFiled: June 16, 2023Publication date: February 1, 2024Applicant: 10X Genomics, Inc.Inventors: Joshua DELANEY, Shalini Gohil, Veronica Emelina Gonzalez Muñoz, Joshua Gu, Albert Dale Kim, Yi Luo, Tathagata Mukherjee, Monica Nagendran, James Francis Perna, III, Kristen Nguyen Pham, Meiliana Tjandra
-
Publication number: 20230287475Abstract: Provided herein are methods for de-crosslinking fixed biological samples (e.g., fixed biological samples including aminal crosslinks). The compositions and methods disclosed can de-crosslink oligonucleotides (e.g., DNA or RNA) or proteins from fixed biological samples (e.g., fixed biological samples with aminal crosslinks), wherein the de-crosslinked biological sample is compatible with and can be used in spatial gene expression analysis.Type: ApplicationFiled: December 22, 2020Publication date: September 14, 2023Inventors: James Michael Chell, Joshua Delaney, Rapolas Spalinskas, Aleksandra Jurek, Meiliana Tjandra
-
Publication number: 20220404245Abstract: Provided herein are methods for de-crosslinking fixed biological samples (e.g., fixed biological samples including aminal crosslinks). The compositions and methods disclosed can de-crosslink oligonucleotides (e.g., DNA or RNA) or proteins from fixed biological samples (e.g., fixed biological samples with aminal crosslinks), wherein the de-crosslinked biological sample is compatible with and can be used in spatial gene expression analysis.Type: ApplicationFiled: August 16, 2022Publication date: December 22, 2022Inventors: James Michael Chell, Joshua Delaney, Rapolas Spalinskas, Aleksandra Jurek, Meiliana Tjandra
-
Publication number: 20210388423Abstract: Provided herein are methods of sequencing comprising click chemistry bioconjugation. In some embodiments, target polynucleotide sequences on the same or different molecules are contacted with and hybridize to probes comprising click functional groups. Probes (e.g., reading probes) hybridizing to adaptor sequences adjacent to different sequences of interest (e.g., barcodes to be sequenced) can be hybridized simultaneously in large pools. In some embodiments, the provided methods achieve multiplexing without requiring separate hybridization of probes (e.g., reading probes) for each sequencing-by-ligation cycle, thereby reducing total hybridization time which is typically a most time-consuming step in in situ technologies. In some aspects, the hybridized probes (e.g., reading probes) are clicked onto detectable probes to analyze a sequence of a target polynucleotide in a sequencing-by-ligation fashion.Type: ApplicationFiled: June 11, 2021Publication date: December 16, 2021Applicant: 10x Genomics, Inc.Inventors: Felice Alessio BAVA, David M. PATTERSON, Meiliana TJANDRA, Yi LUO
-
Publication number: 20210246122Abstract: The present invention relates to triazine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.Type: ApplicationFiled: June 14, 2019Publication date: August 12, 2021Applicant: Aduro Biotech, Inc.Inventors: George Edwin Katibah, Jung Yun Kim, Chudi Obioma Ndubaku, Meiliana Tjandra, Tucker Curran Roberts
-
Publication number: 20210190770Abstract: The present disclosure provides compositions and methods for using fixed biological samples in partition-based assays. In at least one embodiment, the disclosure provides a composition comprising a fixed biological sample and an un-fixing agent contained in a partition, such as a discrete droplet. In some embodiments, the disclosure provides un-fixing agent compounds capable of catalytically cleaving crosslinks in fixed biological samples, particularly crosslinked nucleic acids, such as RNA.Type: ApplicationFiled: December 22, 2020Publication date: June 24, 2021Applicant: 10X Genomics, Inc.Inventors: Joshua DELANEY, Shalini GOHIL, Jill HERSCHLEB, Adam LOWE, Albert KIM, Meiliana TJANDRA
-
Publication number: 20200276169Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.Type: ApplicationFiled: March 19, 2020Publication date: September 3, 2020Inventors: Virender Singh AULAKH, Anthony CASAREZ, Xiaodong LIN, Mika LINDVALL, Glenn MCENROE, Heinz Ernst MOSER, Folkert RECK, Meiliana TJANDRA, Robert Lowell SIMMONS, Aregahegn YIFRU, Qingming ZHU
-
Patent number: 10369138Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.Type: GrantFiled: September 22, 2015Date of Patent: August 6, 2019Assignee: Novartis AGInventors: Virender Singh Aulakh, Anthony Casarez, Xiaodong Lin, Mika Lindvall, Glenn McEnroe, Heinz Ernst Moser, Folkert Reck, Meiliana Tjandra, Robert Lowell Simmons, Aregahegn Yifru, Qingming Zhu
-
Publication number: 20190231752Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.Type: ApplicationFiled: April 10, 2019Publication date: August 1, 2019Inventors: Virender Singh AULAKH, Anthony CASAREZ, Xiaodong LIN, Mika LINDVALL, Glenn MCENROE, Heinz Ernst MOSER, Folkert RECK, Meiliana TJANDRA, Robert Lowell SIMMONS, Aregahegn YIFRU, Qingming ZHU
-
Patent number: 9566312Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, and A-B are as defined herein, which are non-immunosuppressive, cyclophilin-binding, mPTP blockers and are therefore useful for the prevention or treatment of diseases or disorders such as HCV infection, stroke, multiple sclerosis, HBV infection, HPV infection, asthma, cancer, muscular dystrophy, sepsis, ischemia/reperfusion injury, and heart failure.Type: GrantFiled: May 20, 2015Date of Patent: February 14, 2017Assignee: Novartis AGInventors: Jiping Fu, Subramanian Karur, Xiaolin Li, Peichao Lu, Wosenu Mergo, Alexey Rivkin, Zachary Kevin Sweeney, Meiliana Tjandra, Andrew Weiss, Aregahegn Yifru
-
Publication number: 20160051523Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.Type: ApplicationFiled: September 22, 2015Publication date: February 25, 2016Applicant: NOVARTIS AGInventors: Virender Singh AULAKH, Anthony CASAREZ, Xiaodong LIN, Mika LINDVALL, Glenn MCENROE, Heinz Ernst MOSER, Folkert RECK, Meiliana TJANDRA, Robert Lowell SIMMONS, Aregahegn YIFRU, Qingming ZHU
-
Patent number: 9174978Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.Type: GrantFiled: March 23, 2015Date of Patent: November 3, 2015Assignee: Novartis AGInventors: Virender Singh Aulakh, Anthony Casarez, Xiaodong Lin, Mika Lindvall, Glenn McEnroe, Heinz Ernst Moser, Folkert Reck, Meiliana Tjandra, Robert Lowell Simmons, Aregahegn Yifru, Qingming Zhu
-
Publication number: 20150306172Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, and A-B are as defined herein, which are non-immunosuppressive, cyclophilin-binding, mPTP blockers and are therefore useful for the prevention or treatment of diseases or disorders such as HCV infection, stroke, multiple sclerosis, HBV infection, HPV infection, asthma, cancer, muscular dystrophy, sepsis, ischemia/reperfusion injury, and heart failure.Type: ApplicationFiled: May 20, 2015Publication date: October 29, 2015Applicant: NOVARTIS AGInventors: Jiping Fu, Subramanian Karur, Xiaolin Li, Peichao Lu, Wosenu Mergo, Alexey Rivkin, Zachary Kevin Sweeney, Meiliana Tjandra, Andrew Weiss, Aregahegn Yifru
-
Publication number: 20150266867Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.Type: ApplicationFiled: March 23, 2015Publication date: September 24, 2015Applicant: NOVARTIS AGInventors: Virender Singh AULAKH, Anthony CASAREZ, Xiaodong LIN, Mika LINDVALL, Glenn MCENROE, Heinz Ernst MOSER, Folkert RECK, Meiliana TJANDRA, Robert Lowell SIMMONS, Aregahegn YIFRU, Qingming ZHU
-
Patent number: 9072696Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, R4, R5, and A-B are defined herein, which are non-immunosuppresive, cyclophilin-binding, mPTP blockers and are therefore useful for the prevention or treatment of diseases or disorders such as HCV infection, stroke, multiple sclerosis, HBV infection, HPV infection, asthma, cancer, muscular dystrophy, sepsis, ischemia/reperfusion injury, and heart failure.Type: GrantFiled: September 26, 2013Date of Patent: July 7, 2015Assignee: Novartis AGInventors: Jiping Fu, Subramanian Karur, Xiaolin Li, Peichao Lu, Wosenu Mergo, Alexey Rivkin, Zachary Kevin Sweeney, Meiliana Tjandra, Andrew Weiss, Aregahegn Yifru
-
Publication number: 20140134132Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, R4, R5, and A-B are defined herein, which are non-immunosuppresive, cyclophilin-binding, mPTP blockers and are therefore useful for the prevention or treatment of diseases or disorders such as HCV infection, stroke, multiple sclerosis, HBV infection, HPV infection, asthma, cancer, muscular dystrophy, sepsis, ischemia/reperfusion injury, and heart failure.Type: ApplicationFiled: September 26, 2013Publication date: May 15, 2014Applicant: NOVARTIS AGInventors: Jiping Fu, Subramanian Karur, Xiaolin Li, Peichao Lu, Wosenu Mergo, Alexey Rivkin, Zachary Kevin Sweeney, Meiliana Tjandra, Andrew Weiss, Aregahegn Yifru